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A B S T R A C TObjective: The aim of this study was to identify, from a health care
perspective, the cost of treatment for chronic lymphocytic leukemia in
specialized hospitals in Ukraine. Methods: Cost analysis was per-
formed by using retrospective data between 2006 and 2010 from
patient-ﬁle databases of two specialized hospitals (145 patients).
Uncertainty was assessed by using bootstrapping and multivariate
sensitivity analyses. Linear regression analysis was used to analyze
whether patients’ characteristics are related to health care costs. In
addition, one-way analysis of variance (Welch test) and paired-
sample t test were conducted to compare mean costs of treatment
between the two hospitals and mean expenses for drugs and in-
hospital stay. Results: The average annual cost for a patient’s drug
treatment is 2047 EUR. The cost of hospitalization was signiﬁcantly
lower (t ¼ 5.026; signiﬁcance two-tailed ¼ 0.000) and equal to 541 EUR
per person, resulting in total expenditures of 2589 EUR. Mean total
costs in the bootstrap analysis were equal to 2584 EUR (median 2576see front matter Copyright & 2013, International S
r Inc.
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ondence to: Olena Mandrik, Danylo Halytsky Lviv NaEUR, 97.5th percentile 3223 EUR; 2.5th percentile 1987 EUR). The
regression analysis did not reveal a relation between patients’ char-
acteristics and health care costs, although hospital choice was an
inﬂuential parameter (β ¼ −0.260; signiﬁcance ¼ 0.002). Signiﬁcant
difference in mean costs of two analyzed hospitals was also con-
ﬁrmed by one-way analysis of variance (Welch statistics 19.222, P ¼
0.000). Conclusions: Drug treatment comprises the largest portion of
total costs, but differences between hospitals exist. Because many
patients in Ukraine pay out of pocket for in-hospital drugs, these costs
are a high economic burden for patients with chronic lymphocytic
leukemia.
Keywords: chronic lymphocytic leukemia, cost of treatment, hematologic
malignancies.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Globally, there are approximately 7.4 million cancer deaths per
year, which is approximately 13% of deaths from all causes.
Because the population of many countries around the world is
aging, it can be expected that cancer incidence will increase [1].
Among oncologic diseases, chronic hematologic malignancies are
comparatively rare. In Ukraine in 2010 the ofﬁcially registered
total morbidity rate for patients with diagnosed leukemia was 7.8
per 100,000 people, of which 39.3% did not live a year after
diagnosis [2]. Chronic lymphocytic leukemia (CLL) is the most
frequent form of leukemia in Western countries, and it accounts
for approximately 30% to 40% of all leukemias [3,4]. It is charac-
terized by the clonal proliferation and accumulation of neoplastic
B lymphocytes in the blood, bone marrow, lymph nodes, and
spleen. Although the median age of patients at diagnosis is
higher than retirement age and so has no signiﬁcant impact on
state productivity loss [5], the economic impact of CLL is signiﬁ-
cant due to long duration and high expenses related to treatment,
combined with low cure rates. Nevertheless, early diagnosis and
effective treatment of hematologic malignancies shift theindicators of a patient’s life expectancy to positive values [6].
For example, in the United States for the time period 1999 to 2005,
the 5-year survival rate for leukemia was 82% (79% for CLL),
although in the time period 1975 to 1977, this indicator was close
to Ukrainian data—35% [7,8].
In-hospital medical care for patients with CLL is generally
provided in 35 hematologic departments, based in district hospi-
tals (16), state city hospitals (12), oncologic dispensaries (4), and
specialized institutes of the National Academy of Medical Science
of Ukraine (3) [2,9]. To the latter group belong two hematologic
institutes and the National Cancer Institute, which is a leading
state institution additionally responsible for methodological and
scientiﬁc development in this clinical area. Treatment schemes
for patients with CLL are based on a clinical protocol that
proposes a number of treatment options for patients with CLL
and was ﬁrst developed and approved under an order of the
Ministry of Health of Ukraine in 2010 [10]. State pharmaceutical
provision for adult oncologic patients is granted through the
national treatment program “Oncology” for the years 2011 to
2016, although governmental ﬁnancing is insufﬁcient and drug
treatment is usually paid out of pocket by patients [11].ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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life [12,13], studies exploring economic costs and burden of
hematologic malignancies are relatively rare in English-
language publications worldwide [14,15]. Possible reasons for this
lack of information appear to include the low incidence rate and
aged study population (over 60 years old), which make broad,
well-designed economic analyses a challenge for most research-
ers [5,16]. These few cost reviews identiﬁed cost drivers for CLL as
chemotherapy costs, intravenous immunoglobulin costs, trans-
plantation costs, and costs associated with the differential stain-
ing cytotoxicity assay, with the main cost drivers related to the
treatment chosen [14–16].
The health care system itself, including organization of
medical care for oncologic patients, is going through a stage of
transformation. Changes include the implementation of a uni-
versal reimbursement system to begin in 2016, standardization of
medical help with enhanced control on follow-up of clinical
protocols, and more strict division between primary, secondary,
and tertiary levels of medical help. Considering that the major
recipients of the central state budget are specialized institutions
(tertiary level of help), the primary aim of this research was to
identify the cost of treatment for CLL in specialized hospitals in
Ukraine from a health care perspective and to understand
whether patient characteristics are related to these costs.Methods
The study was conducted from a health care perspective,
accounting for direct medical costs to illustrate which costs will
be paid by the Ministry of Health after the health care system
transformation.
Analysis included data from databases of two specialized
hospitals—National Cancer Institute and State Institute of Hem-
atology—that receive state ﬁnancing through the national treat-
ment program “Oncology.” These hospital databases were made
in the programs Access and Word for the purpose of data storage
and included all the information available in hard copies of
hospital cards; the data were typed into the hospital databases
retrospectively by qualiﬁed personnel (hospital assistants). After-
ward, data from the two hospital databases were transferred into
Excel, and SPSS databases were created for the purpose of data
analysis.
The study population included all newly diagnosed and
relapsed patients with CLL (145 in total) who were hospitalized
during the period from 2006 to 2010 and whose data were
recorded in the electronic database. The information derived
from the hospital cards (excluding patients’ identiﬁcation infor-
mation) contained the following data: sex of the patient, age
during diagnosis and treatment, number of years a patient lives
with the disease, year of treatment, therapies prescribed and
duration of treatment, the number of hospitalizations per year,
and the duration of hospitalization. Stage of the patient’s disease
and health state on Eastern Cooperative Oncology Group (ECOG)
performance status were excluded from the factor list because
data on these parameters were frequently missing.
Costs related only to CLL diagnosis for the last observational
year were calculated. These costs included drug expenses and in-
hospital costs. The cost of diagnostics, medical procedures, hotel
services, and medical personnel is included in the integral in-
hospital cost, based on data of the economic department of the
National Cancer Institute. These costs reﬂect the approximate
costs for oncologic patients in a specialized hospital and are
equal to 16.3 EUR per patient-day [17]. Out-of-hospital health care
costs were not calculated because according to the clinical
protocol [10], the treatment of patients with CLL should be
conducted only in hospital. The average length of hospital stayand drug costs were assessed by retrospective analysis of patient
ﬁle data.
To assess drug usage, daily deﬁned doses and total amount
received during the year were recorded. To calculate drug costs,
we used a stepwise approach to determine an average price,
depending on the availability of information: tariff in govern-
mental purchases (2010); price, registered in the Ministry of
Health; and distributors’ price.
Multivariate sensitivity analysis was conducted. Price devia-
tions for the sensitivity test of all drugs were calculated by using
the minimum and maximum prices from the available sources
(hospital purchases, state registered prices, and distributors’
prices). There are no deﬁned general tariffs for hospital stay in
Ukraine, which are relatively low in comparison to medical costs
in the European countries and may vary from 3.4 to 19.2 EUR [17–
19]. All statistical analyses were performed in IBM SPSS Statistics
20 (SPSS, Inc., Chicago, IL), and bootstrapping (1000 replications)
was performed in Microsoft Excel 2010. To analyze whether
choice of the hospital and age and sex of a patient have an
impact on total health care costs, logarithmic data transforma-
tion was performed on nonnormally distributed costs and a
linear regression analysis was applied. Because of frequently
missing data for the parameter “stage of the disease,” as a proxy
for disease progression we included “number of years a patient is
living with the disease” in the linear regression analysis. Based
on Cook’s distance (0.028571), which measures the effect of
deleting a given observation and so allows to deﬁne data points
with large residuals, we excluded six outliers to improve the
residuals plot and model validity. One-way analysis of variance
(Welch test) was conducted to compare mean costs of treatment
in the two hospitals involved (asymptotically F distributed).
Paired-sample t test was used to compare difference in mean
expenses for drugs and in-hospital stay.Results
Overall, data of 113 patients from the ﬁrst hospital (State
Hematology Institute) and of 32 patients from the second hospital
(National Cancer Institute) were analyzed. Patients were aged 40
to 85 years (mean age 62.9 years, mean age during diagnosis 60.3
years, SD 9.8 years). From the sample, 27.6% (40) of the patients
were newly diagnosed. Because of limited sample size, the
distribution of patients by sex was not equal in different age
groups, with the total proportion of men being equal to 60.7%
(88 men).
Values of the cost items (drugs) and cost deviations for the
sensitivity test are presented in Table 1. As can be seen in Table 1,
the highest cost per milligram was for ﬂudarabine, vincristine,
and rituximab. Rituximab and ﬂudarabine (if Fludara was pre-
scribed) had the highest price per average daily dose, equal to
312.03 EUR for ﬂudarabine and 237.93 EUR for rituximab. Because
drug expenditures depend not only on cost per item but also on
total volume used, we present cost-items utilization and charac-
teristics of population using it in Table 2. Data are presented for
items that were used by more than 3% of patients. Cyclophos-
phamide, ﬂudarabine, and vincristine were prescribed to most of
the patients. Characteristics of the study population using spe-
ciﬁc cost items showed a signiﬁcant difference in the percentage
of men prescribed cyclophosphamide, mitoxantrone, and chlor-
ambucil in comparison to other drugs. No signiﬁcant difference in
the patients’ age was observed, although on average the age of
patients receiving alemtuzumab was lower and of those receiving
chlorambucil was higher. From Table 2 it also may be observed
that the injectable form of ﬂudarabine is prescribed signiﬁcantly
more than the oral form.
Table 1 – Price values of the drugs for the cost and sensitivity analyses.
Drugs* Base-case price
(EUR per mg)
Range used in sensitivity
analysis (EUR per mg)
Source†
Alemtuzumab (inj.) 0.4500 – Tariff in governmental purchases 2010
Bleomycin (inj.) 1.5100 1.5100–1.6300 Distributors’ price
Chlorambucil 0.0080 0.0080–0.2290 Tariff in governmental purchases 2010
Cyclophosphamide (Adriablastine) 1.0600 0.6700–1.4500 Price, registered in the MOH
Cyclophosphamide (other generics) 0.0077 0.0010–0.0120 Tariff in governmental purchases 2010
Dexamethasone (inj.) 0.0200 0.0040–0.0840 Price, registered in the MOH
Dexamethasone (po) 0.0002 – Price, registered in the MOH
Doxorubicin (inj.) 0.1300 0.1300–0.4400 Tariff in governmental purchases 2010
Etoposide phosphate (po) 0.1000 0.0980–0.1000 Price, registered in the MOH
Fludarabine (Fludara inj.) 3.7400 3.2200–3.7400 Tariff in governmental purchases 2010
Fludarabine (Netran inj.) 0.7700 – Tariff in governmental purchases 2010
Fludarabine (Netran po) 0.1500 – Tariff in governmental purchases 2010
Fludarabine (other generics) 2.7800 0.7600–3.3700 Price, registered in the MOH
Methylprednisolone (inj.) 0.1100 0.0140–0.1100 Price, registered in the MOH
Methylprednisolone (po) 0.0260 0.0220–0.0300 Price, registered in the MOH
Mitoxantrone (inj.) 0.3800 0.3800–3.8300 Tariff in governmental purchases 2010
Prednisolone (inj.) 0.0160 0.0130–0.0170 Price, registered in the MOH
Prednisolone (po) 0.0072 0.0072–0.0077 Price, registered in the MOH
Rituximab (inj.) 2.0300 1.3500–2.9600 Tariff in governmental purchases 2010
Vincristine (inj.) 3.6700 2.8600–4.0600 Tariff in governmental purchases 2010
Vinblastine (inj.) 0.6300 0.4000–0.6300 Price, registered in the MOH
inj., injection; MOH, Ministry of Health; po, per os (by mouth).
 Trade name is indicated if the product was prescribed speciﬁcally by it.
† To value the use of the drugs from a health care perspective, we used a stepwise approach to determine an average price, depending on the
availability of information: tariff in governmental purchases (2010); price registered in the MOH; distributors’ price.
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EUR. The average cost of in-hospital stay is 542 EUR per person,
resulting in total expenditures of 2589 EUR. Results indicate that
expenses for drugs signiﬁcantly exceed hospitalization costs (t ¼
5.026; signiﬁcance two-tailed ¼ 0.000).
Mean total cost in the bootstrap analysis was 2584 EUR
(median 2576, 97.5th percentile 3223 EUR; 2.5th percentile 1987
EUR). Sex of the patient, number of years a patient lives with the
disease, and age at the time of hospitalization had no signiﬁcant
impact on health care costs per patient. Hospital choice (β ¼
−0.260; signiﬁcance ¼ 0.002), however, was a strong determinant
of health care costs. One-way analysis of variance also showed a
signiﬁcant difference in mean costs between the two hospitals
involved (Welch statistics 19.222, P ¼ 0.000).
The results of the multivariate sensitivity analysis showed
that in the best-case (lowest cost) scenario, the average annual
spending on drug treatment of a patient with CLL is 1659 EUR,
and in the worst-case scenario, it is 2332 EUR. The deviation of
drug costs does not exceed 12% on the negative side and 19% on
the positive side. The annual cost of hospitalization ranges from
251 to 597 EUR per person and depends on the type of hospital at
which a patient is treated.Discussion
A literature review was conducted in the database PubMed to
explore whether our results were consistent with results from
studies in other countries and to understand whether factors that
impact the cost of other cancer conditions are similar to those
affecting CLL. The search was limited to a 10-year period of English-
language articles studying multiple cancer conditions. The literature
review showed that the major factors inﬂuencing the cost of cancer
conditions are related to patients’ characteristics, such as stage at
diagnosis and stage at treatment, degree of comorbidity, age andgender of a patient, and tumor site. Lal et al. [20], Longo et al. [21,22],
and Yabroff et al. [23] recorded increased costs due to higher stage
of the disease during treatment. Akushevich et al. [24], in a
retrospective analysis on oncologic patients in the United States,
determined that the highest costs exist in the period of treatment
immediately after diagnosis. Yabroff et al. [23] also recorded that
both the ﬁrst stage and the last stage of the disease at the time of
treatment are associated with higher costs. The results of the
studies by Lal et al. [20] and Kuse et al. [25] demonstrated a
connection between the degree of comorbidity and treatment costs.
The impact of patient’s age on the cost of cancer was signiﬁcant in a
number of studies, but differed in scale and type of impact [20–
22,24,25]. Some research described an impact of tumor site on total
costs of the diseases [21,22,24]. Yabroff et al. [23] showed that cost
for the treatment of localized diseases is lower, a conclusion
supported by Lai et al. [20] who noted that the highest costs were
for hematological malignancies among other types of cancer.
A limited number of economic analyses that describe factors
inﬂuencing the cost of CLL treatment speciﬁcally were found.
These studies showed a positive correlation between age and
cost of drug treatment [6,26]. Danese et al. [26] also concluded
that male gender is associated with higher cost for CLL drug
treatment.
Similar to Yabroff et al. [23], CLL phase-speciﬁc health care
costs for the US-Medicare population were found to have a U-
shaped pattern over lifetime [27]. A study in the United States by
Lafeuille et al. [27] also reported signiﬁcantly higher health care
costs for a CLL population compared to matched controls, mainly
because of the higher costs for physicians, caregivers, and
inpatient care. Besides inpatient hospital stay, pharmaceuticals
were the main cost drivers of CLL in a study in Germany [28],
where the cost of treatment per case is about twice as high as the
cost per case for highly prevalent diseases, such as chronic
obstructive pulmonary disease or diabetes. This study also
revealed that the average annual cost for patients with CLL from
Table 2 – Drug utilization related to patients’ population characteristics.
Drugs* Patients
using the
drug (%)
Average age (SD) of
patients using this
item (y)
n (%)
Mean
volume per
patient (mg)
Men among ones
who are using this
drug
Prescriptions during
the ﬁrst year of
treatment
Alemtuzumab (inj.) 10.3 57.90  9.25 9 (60.00) 0 (0.00) 87.14
Chlorambucil (po) 7.6 74.45  4.61 5 (45.50) 6 (54.5) 4.76
Cyclophosphamide
(Adriablastine inj.)
4.8 64.29  5.85 6 (85.70) 4 (57.10) 7.24
Cyclophosphamide
(all brand names)
66.2 62.95  9.13 59 (61.50) 29 (30.20) 2900.34
Dexamethasone
(inj.)
10.0 60.07  8.71 19 (65.50) 7 (24.10) 22.70
Dexamethasone (po) 5.4 59.20  6.50 3 (60.00) 1 (20.00) 4.41
Fludarabine (Fludara
inj.)
44.4 60.56  8.82 36 (57.10) 13 (20.60) 377.87
Fludarabine (po) 3.4 59.80  8.35 3 (60.00) 0 (0.00) 30.48
Fludarabine inj. (all
brand names)
47.6 60.65  8.82 40 (58.00) 13 (18.80) 411.79
Methylprednisolone
(po)
4.8 56.29  10.42 4 (57.1) 1 (14.3) 22.59
Mitoxantrone (inj.) 5.5 58.12  6.31 7 (87.50) 0 (0.00) 4.35
Prednisolone (inj.) 5.5 60.63  10.64 5 (62.50) 2 (25.00) 224.63
Prednisolone (po) 26.2 66.63  8.07 26 (68.40) 14 (36.80) 179.37
Rituximab (inj.) 12.4 59.28  6.72 13 (72.20) 5 (27.80) 258.62
Vincristine (inj.) 31.0 64.51 9.57 34 (75.60) 17 (37.80) 1.66
inj., injection; po, per os (by mouth).
 Trade name is indicated if a product was prescribed not by generic but by a trade name with a high frequency (for cyclophosphamide and
ﬂudarabine).
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 2 0 5 – 2 0 9208the sickness fund perspective decreased with increasing age until
60 to 65 years, and thereafter increased.
Results of these US and German studies [27,28] differed from
the results of our analysis conducted in Ukraine, where the cost
of medical care is relatively low and the major expenses are drug
related. Similar to our results, a literature review conducted by
Stephens et al. [16] concluded that the cost of drug therapy is the
main driver for CLL treatment costs, signiﬁcantly exceeding
hospitalization costs.
Previous research has suggested that the major factors
inﬂuencing the cost of cancer conditions are stage at diagnosis
and stage at treatment, degree of comorbidity, age and gender,
tumor site, and type of therapy received. Our study on a
Ukrainian sample from two specialized institutions, however,
showed that only hospital choice had a signiﬁcant impact on the
cost of drug treatment. Possible explanations may be risk-patient
selection or difference in treatment practice within the hospitals.
High usage of injectable forms of drugs such as ﬂudarabine and
dexamethasone also was observed in this study. Because no
health technology assessment agency currently exists, there are
no recommendations comparing injectable and oral forms devel-
oped in Ukraine. Nevertheless, the National Institute for Health
and Clinical Excellence [29] recommends giving preference to the
oral form of ﬂudarabine because of its higher efﬁciency. Ration-
ality of the use of the injectable form of ﬂudarabine in CLL
treatment practice may be a potential topic for further research
in Ukraine.
Ukraine is a country with a post-Semashko model of the
health care system, and currently there is no state reimburse-
ment system. Limited reimbursement for in-hospital treatment,
however, is provided under governmental programs for such
diseases as AIDS, tuberculosis, diabetes, cardiovascular diseases,and cancer, among other diseases. These in-hospital state
purchases cover from 7% to 40% of oncologic patients’ needs
depending on the region and hospital type [30,31]. Major
expenses on drugs are covered by patients’ out-of-pocket pay-
ments. Thus, the high treatment cost of chronic conditions such
as CLL may be a signiﬁcant economic burden, especially for
patients with low income.
The average annual cost of drug treatment for patients with
CLL is 2047 EUR, with the majority of costs paid out of pocket.
From December 1, 2011, the minimum annual subsistence level
in Ukraine is equal to 1155 EUR for people of working age and 920
EUR for those who are retired. These ﬁgures are lower than
annual costs of drug treatment for patients with CLL in Ukraine,
according to current clinical practice in specialized hospitals.
This may impose a signiﬁcant economic impact of the disease on
vulnerable populations (e.g., elderly poor), taking into account
only limited governmental subsidy. With high costs for the
treatment of hematologic malignancies [15,26], and insufﬁcient
reimbursement level for drug treatment in Ukraine [9], the treat-
ment of CLL in specialized hospitals may be ﬁnancially difﬁcult
for economically unprotected patients because of high
therapy costs.Implications
Our analysis indicates that there is likely to be a signiﬁcant
difference in the practice of treating CLL within different hospi-
tals of Ukraine, resulting in a signiﬁcant deviation in drug
expenditures. Therefore, it is not clear whether treatment stand-
ards are being followed within the hospitals and whether the
schemes used are evidence based and rational. These issues
should be explored further in future studies.
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Retrospective analysis allowed us to make an estimation of
treatment cost for CLL in specialized medical institutions of
Ukraine and to explore its correlation with patient character-
istics. Our research, however, suffered from several limitations.
First, our research does not allow us to assess the economic
burden of CLL in Ukraine. It is expected that costs of treatment in
the current study may be higher than in the regional oncology
dispensaries because of larger state subsidiaries and patients’
expenditures on drugs.
Moreover, data on stage of the patient’s disease and health
state on Eastern Cooperative Oncology Group (ECOG) criterion
were missing and thus excluded from the factor list. It is possible,
however, that these factors may have an impact on CLL costs.
We conducted a linear regression analysis on logarithmic-
transformed costs data while excluding six outliers on the basis
of Cook’s distance. Disregarding these six observations may have
increased the signiﬁcance of the statistical analysis and the
strength of the relation between the independent variable (hos-
pital choice) and the dependent variable (health care costs).Conclusions
Drug treatment comprises the largest portion of total costs, which
presumably may be a high economic burden for a patient with CLL
who is the major payer of treatment expenses in Ukraine. Costs of
drug treatment signiﬁcantly depend on the type of hospital selected.Acknowledgment
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